Tags

Type your tag names separated by a space and hit enter

Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas.
J Clin Endocrinol Metab. 1986 Nov; 63(5):1071-4.JC

Abstract

SMS 201-995 is a new somatostatin analog which is 10-60 times more potent and specific than somatostatin as an inhibitor of GH and insulin release. The aim of this study was to assess its value as an adjunct to insulin therapy in insulin-dependent diabetic- (IDD) patients. Six IDD patients were studied. Their average insulin doses ranged from 22-46 U/day, and hemoglobin A1c levels varied between 6.5-11.5%. Two patients had background retinopathy and mild sensorimotor neuropathy. After 12 h of glucemic stabilization, the patients were kept normoglycemic by connecting them to the Biostator-GCIIS. The study entailed two parts in random order, in which standardised mixed meals were administered at 0800, 1400, and 2000 h with or without sc bolus injections of 50 micrograms SMS 201-995 immediately before meal ingestion. Plasma free insulin, C-peptide, GH, and glucagon were measured by RIA. Postprandial hyperglycemia was significantly diminished by SMS 201-995 after breakfast, lunch, and dinner. Insulin requirements, both total and 2-h postprandially, decreased significantly with a parallel reduction in free insulin levels. Postprandial glucagon levels also significantly decreased, but GH profiles were similar. In conclusion, the somatostatin analog SMS 201-995 has a potential value as an adjunct to insulin in the management of IDD patients.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2876005

Citation

Rios, M S., et al. "Somatostatin Analog SMS 201-995 and Insulin Needs in Insulin-dependent Diabetic Patients Studied By Means of an Artificial Pancreas." The Journal of Clinical Endocrinology and Metabolism, vol. 63, no. 5, 1986, pp. 1071-4.
Rios MS, Navascues I, Saban J, et al. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. J Clin Endocrinol Metab. 1986;63(5):1071-4.
Rios, M. S., Navascues, I., Saban, J., Ordoñez, A., Sevilla, F., & Del Pozo, E. (1986). Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. The Journal of Clinical Endocrinology and Metabolism, 63(5), 1071-4.
Rios MS, et al. Somatostatin Analog SMS 201-995 and Insulin Needs in Insulin-dependent Diabetic Patients Studied By Means of an Artificial Pancreas. J Clin Endocrinol Metab. 1986;63(5):1071-4. PubMed PMID: 2876005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. AU - Rios,M S, AU - Navascues,I, AU - Saban,J, AU - Ordoñez,A, AU - Sevilla,F, AU - Del Pozo,E, PY - 1986/11/1/pubmed PY - 1986/11/1/medline PY - 1986/11/1/entrez SP - 1071 EP - 4 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 63 IS - 5 N2 - SMS 201-995 is a new somatostatin analog which is 10-60 times more potent and specific than somatostatin as an inhibitor of GH and insulin release. The aim of this study was to assess its value as an adjunct to insulin therapy in insulin-dependent diabetic- (IDD) patients. Six IDD patients were studied. Their average insulin doses ranged from 22-46 U/day, and hemoglobin A1c levels varied between 6.5-11.5%. Two patients had background retinopathy and mild sensorimotor neuropathy. After 12 h of glucemic stabilization, the patients were kept normoglycemic by connecting them to the Biostator-GCIIS. The study entailed two parts in random order, in which standardised mixed meals were administered at 0800, 1400, and 2000 h with or without sc bolus injections of 50 micrograms SMS 201-995 immediately before meal ingestion. Plasma free insulin, C-peptide, GH, and glucagon were measured by RIA. Postprandial hyperglycemia was significantly diminished by SMS 201-995 after breakfast, lunch, and dinner. Insulin requirements, both total and 2-h postprandially, decreased significantly with a parallel reduction in free insulin levels. Postprandial glucagon levels also significantly decreased, but GH profiles were similar. In conclusion, the somatostatin analog SMS 201-995 has a potential value as an adjunct to insulin in the management of IDD patients. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/2876005/Somatostatin_analog_SMS_201_995_and_insulin_needs_in_insulin_dependent_diabetic_patients_studied_by_means_of_an_artificial_pancreas_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-63-5-1071 DB - PRIME DP - Unbound Medicine ER -